 Background Kidney cancer in adults has a high metastatic potential with poor survival rates. Pronostic factors would improve the choice of a therapeutic method. We decided to revisit epidemiology and evaluate survival factors in kidney metastatic carcinomas in a Moroccan setting.  Method: Retrospective data collect from 2017 to 2020 of all adults patients presenting with metastatic kidney carcinomas. Epidemiology and survival rates were analysed using SPSS.  Results: We included 79 patients, predominantly over 60yo and male. Metastases were observed in lungs (73.4%), lymph nodes (39.2%), livers (31.6%), bones (35.4%) and peritoneum (17.8%). Metastases were concurrent to the primitive tumor in 59.5%. Histology was predominantly clear cell renal carcinoma. According to IMDC score, 77% of patients had an intermediate score. Global survival was 29%, better for patients with an intermediate score (p=0.009) as well as progression free survival (p=0.001). In multivariate analysis, only the OMS performance status (p=0.008) and height (0.02) were associated with survival.  Conclusion Thé IMDC score is a suitable tool to classify patients with metastatic kidney cancers, in order to guide therapeutic choices.